Drug Profile


Alternative Names: 6720 CDRI; Levomeloxifene; NNC 460020

Latest Information Update: 15 Jan 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Central Drug Research Institute
  • Developer Novo Nordisk; Novo Nordisk Pharma; Takeda
  • Class Pyrrolidines
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 15 Jan 2003 A study investigating the incidence of adverse events has been added to the adverse events section
  • 13 Oct 1998 Discontinued-I for Postmenopausal osteoporosis in Japan (PO)
  • 29 Sep 1998 Discontinued-III for Postmenopausal osteoporosis in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top